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Increased oxidative phosphorylation in an iPSC- derived model of Rothmund-Thomson
syndrome associated osteosarcomagenesis

Brittany Ellis Jewell, BS

Advisory Professor: Dung-Fang Lee, Ph.D.

Osteosarcoma is the most common bone malignancy in children and adolescents
worldwide. Patients with Type II Rothmund-Thomson Syndrome (RTS) are highly
predisposed to develop osteosarcoma, with 30% of patients in the largest cohort study
developing osteosarcoma. Patients with Type II RTS have biallelic mutations in the DNA
helicase RECQL4, which has been shown to have mitochondrial functions that include DNA
replication and repair.
We describe the generation of 12 induced pluripotent stem cell lines (iPSCs) from
two paired RTS patient/ parental control (Family) sets. These iPSCs were validated, then
differentiated to the bone precursor, mesenchymal stem cells (MSCs). After verification of
the MSCs, we differentiated the MSCs to osteoblasts, which are thought to be the cells that
form osteosarcoma. We hypothesized that transcriptional changes that occur during
differentiation may be important during osteosarcomagenesis. During differentiation,
increased oxidative phosphorylation related genes, specifically transcription of genes which
encode complex I of the electron transport chain, were upregulated. We next demonstrated
that the observed transcriptional changes led to phenotypic changes in enzyme activity. We
then explored the nature of oxidative phosphorylation and glycolysis in RTS osteoblasts and
found that maximal respiration and ATP production increased compared to Family
osteoblasts. We then sought to explore inhibitors of oxidative phosphorylation that might
reverse the phenotype of ATP production preferentially through the electron transport chain.
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We utilized the specific inhibitor of complex I, IACS-010759, and examined the nature of
oxidative phosphorylation after treatment. We found significantly decreased maximal
respiration and cell proliferation after treatment at physiological doses. Transcriptional
changes that occurred after treatment demonstrated a decrease in cell cycling and tumorpromoting pathways and a restoration of normal cellular processes, including upregulation in
genes that may prevent tumor formation. This study helps shed light on the longunderstudied molecular pathogenesis of osteosarcoma and provides new insights for a
more specific and clinically relevant therapeutic.
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Chapter One: Introduction

Figures and text are partially reprinted from Lin, Y.H.*, Jewell, B.E.*, Gingold, J., Lu, L.,
Zhao, R., Wang, L.L., and Lee, D.F. (2017). Osteosarcoma: Molecular Pathogenesis and
iPSC Modeling. Trends Mol Med 23, 737-755. *co-first authors

1

Osteosarcoma is one of the most frequent primary malignant tumors in childhood
and adolescence. A poorly defined molecular mechanism and insufficient models have
resulted in very few therapeutic options for this potentially lethal disease. The osteosarcoma
survival rate has not changed in 40 years (Mirabello et al., 2009b), demonstrating the need
for improved models and detailed molecular studies. In this study, we describe a novel
model of Type II Rothmund-Thomson Syndrome (RTS) associated osteosarcoma that will
allow us to address the current gap in knowledge regarding the molecular mechanisms of
osteosarcoma initiation and progression. The model makes use of induced pluripotent stem
cells (iPSCs) derived from dermal fibroblasts of patients with RTS.
Modeling human disease using patient-derived iPSCs is at the forefront of
personalized medicine, as it allows for the production of somatic cells with complete genetic
fidelity to the patients from which they are derived. In short, patient dermal fibroblasts are
cultured and reprogrammed, yielding iPSCs, which then can differentiate into osteoblaststhe precursors of osteosarcoma. The monogenetic nature of RTS associated osteosarcoma
makes an iPSC approach especially advantageous. It provides an infinite source of nonimmortalized cells suitable for inquiry into the molecular pathophysiology of this disease and
ultimately provides a platform for further study of therapeutic approaches.
Type II RTS is a rare genetic disorder with an osteosarcoma predisposition in which
all patients share mutations in RECQL4, which encodes one of five human RecQ DNA
helicases (Chu and Hickson, 2009). Type II RTS patients are highly predisposed to
developing osteosarcoma, making them an ideal cohort to better understand the molecular
mechanisms underlying this malignancy (Lu et al., 2020). We hypothesized that RTS
patient-derived iPSCs can be used to model osteosarcomagenesis caused by the
dysregulation of pathways that are altered in RECQL4 mutated osteoblasts, which could
attribute to osteosarcoma development. Furthermore, we hypothesized that these altered
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cellular pathways would shed light on a targetable molecule that could be taken advantage
of in the hopes of a new potential treatment for osteosarcoma.

1.1

Osteosarcoma
Osteosarcoma is the most common pediatric bone malignancy, affecting about 4 per

million children per year, worldwide (Mirabello et al., 2009a). Despite the prevalence,
osteosarcoma survival rates have remained unchanged for over three decades.
Osteosarcoma survival rates continue to hover around 70%, while survival after metastasis
is about 30% (Lin et al., 2017b). This is largely due to the lack of new treatments, limited by
the identification of suitable targets for treatment (Zhao et al., 2020). Such targets can be
identified by a more thorough understanding of the molecular mechanism of
osteosarcomagenesis. Osteosarcoma is a bone forming tumor that presents as increased
opacity upon radiographic imaging via X-ray. It has been shown that many clonal origins
exist and can propagate simultaneously (Gambera et al., 2018).
There are two primary competing hypotheses regarding the cellular origin of
osteosarcoma, the mesenchymal stem cell (MSC) origin hypothesis and the osteoblast
origin hypothesis (Lee et al., 2015; Rodriguez et al., 2012; Tataria et al., 2006; Xiao et al.,
2013). The MSC hypothesis proposes that a mutation-carrying MSC will give rise to
osteosarcoma (Rodriguez et al., 2012; Xiao et al., 2013). A high frequency of pathogenic
variants in the TP53 and RB1 tumor suppressor genes and the c-MYC and RAS oncogenes
is found in genomic studies of human osteosarcoma (Chen et al., 2014; Kansara et al.,
2014). Moreover, transformed human MSCs engineered to deplete RB1 and overexpress cMYC -- a combination observed in patients with poor survival-- acquire malignant
osteosarcoma-like properties. These MSCs express osteosarcoma markers CD99, ALP,
osteonectin, and osteocalcin (also known as bone gamma-carboxyglutamic acid-containing
protein (BGLAP)). They form lung and liver metastases in immunocompromised mice,
suggesting that MSCs constitute the cellular origin of osteosarcomas (Wang et al., 2017).
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In contrast, the osteoblast origin hypothesis suggests that osteosarcoma arises from
defective differentiation of osteoblast-committed cells. This hypothesis stems from studies of
MSCs derived from Trp53-mutant mice. These studies show that a Trp53 mutation might
result in early osteogenesis. However, a Trp53 mutation impedes final maturation from
osteoblast precursors into mature osteoblasts. This is evaluated by the expression of the
early and intermediate osteogenic marker, osteopontin, rather than the terminal osteogenic
marker, osteocalcin (Tataria et al., 2006). Moreover, during osteogenic differentiation,
depletion of Trp53 or both Trp53 and Rb1 in murine bone marrow-derived MSCs (BMMSCs) - but not adipose-derived MSCs (ASCs) - induces the formation of osteosarcoma-like
tumors (Rubio et al., 2013). Both undifferentiated BM-MSCs and ASCs develop
leiomyosarcoma-like tumors but not osteosarcoma. This finding emphasizes the importance
of osteogenic differentiation of MSCs for osteosarcoma development (Rubio et al., 2013).
Induced pluripotent stem cell (iPSC)-derived osteoblasts, but not MSCs, obtained
from LFS patients maintained in vitro and in vivo tumorigenesis, as demonstrated by an
anchorage-independent growth (AIG) assay and xenotransplantation in
immunocompromised nude mice, respectively (Lee et al., 2015). This suggest that
osteoblasts, rather than MSCs, are the cells of origin for osteosarcoma. Supporting this
notion, RUNX2 and WNT signaling pathways are disrupted in human osteosarcoma
samples. These pathways are essential for osteogenic differentiation. The loss of RUNX2
transcriptional activity and the nuclear accumulation of β-Catenin suggest that
osteosarcoma development might entail differentiation defects (Haydon et al., 2002;
Thomas et al., 2004). In addition, activation of the intracellular domain of Notch1 in
transgenic mice promotes immature osteoblast proliferation and inhibits its maturation. This
process is sufficient to induce osteosarcomagenesis (Tao et al., 2014).
These hypotheses might be reconciled partially if the mutation-carrying MSCs
indirectly result in osteosarcoma by potentiating the generation of osteoblasts with defective
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differentiation. Alternatively, given the variability across osteosarcoma tumor samples, both
MSCs and osteoblasts might contribute to osteosarcomagenesis. TP53 and RB1
conditionally-disrupted MSCs, pre-osteoblasts, and mature osteoblasts are all reported to
develop in osteosarcoma (Quist et al., 2015). Finally, osteosarcoma may arise from mature
osteoblasts and osteocytes. For instance, the osteocyte marker, dentin matrix acidic
phosphoprotein 1 (DMP1), is increased in patient osteosarcoma samples. Additionally,
SV40-immortalized mouse osteocyte cell lines can engraft as a tumor in mice by either
subcutaneous or intratibial injection (Sottnik et al., 2014). Therefore, osteocytes could
possibly constitute an osteosarcoma progenitor cell type. Although there is still a debate
regarding the cellular origins of osteosarcoma, taken together, specific genetic alterations
may represent key factors in driving the development of osteosarcoma across cell types.
Despite the unclear molecular mechanism of osteosarcoma and the uncertain cell-oforigin, one common characteristic of sporadic osteosarcoma is chromosomal alterations.
Kataegis, localized areas of hypermutations, was reported in 50% of osteosarcoma cases
(Chen et al., 2014). Evidence of this phenomenon is supported by other studies (Perry et al.,
2014) and also by studies that find increased incidence of chromothripsis, or increased
chromosomal breakage throughout the chromosomes resulting in rearrangements, in 30%
of osteosarcoma cases (Behjati et al., 2017).
The current standard of care for osteosarcoma treatment is methotrexate,
doxorubicin, and cisplatin. Doxorubicin functions by inducing autophagy and inhibiting
stemness in osteosarcoma cells (Wang et al., 2018). This is accomplished by LncRNA
Sox2OT-V7 via mir-142/ mir-22(Zhu et al., 2020). It is noted further that epigallocatechin
(EGCG), a polyphenol in green tea, has been shown to synergistically combine with
Doxorubicin to increase autophagy (Wang et al., 2018).
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1.2

Rothmund-Thomson Syndrome
Type II Rothmund-Thomson Syndrome (RTS) is a rare autosomal recessive genetic

disorder associated with a 30% prevalence of childhood osteosarcoma. All Type II RTS
patients have biallelic RECQL4 mutations (Wang et al., 2003). RECQL4 is essential for DNA
repair and replication, two processes known to be dysregulated in cancer (Lu et al., 2014).
Because of the high incidence of RTS associated osteosarcoma, we hypothesized
that mutation of RECQL4 plays a significant role in osteosarcomagenesis. Type II RTS
patients with osteosarcoma and sporadic osteosarcoma patients share defining
characteristics including outcomes, histology, primary location, and treatment (Hicks et al.,
2007). Unlike other rare genetic disorders with an osteosarcoma predisposition, Type II RTS
is associated with osteosarcoma largely exclusive of other malignancies (Lu et al., 2020).
This makes Type II RTS patients the ideal cohort in which to study osteosarcomagenesis.
Insights from this study have the potential to provide significant insight into cellular
processes important for sporadic osteosarcoma.

1.3

RECQL4
RTS was described first by Dr. Auguste Rothmund in the late 1800s, who reported

the characteristic rash and cataracts. In the early 1900s, Dr. Sydney Thomson observed the
same rash, in addition to bone abnormalities (Taylor, 1957). Despite the heterogeneity of
osteosarcoma genetic background, 30% of patients in the largest surveillance study of Type
II RTS were diagnosed with osteosarcoma (Lu et al., 2014).
Patients with RTS are diagnosed before two years of age, after presenting with
poikiloderma, shortened stature, sparse hair or eyelashes, and/ or radial ray defects (Wang
et al., 2003; Wang and Plon, 1993) (Figure 1). After diagnosis, directed sequencing is
performed to examine if patients have mutations in ANAPC1 (Ajeawung et al., 2019) or
RECQL4 (Wang et al., 2003), which are associated with Type I and Type II RTS,
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respectively. Type I RTS patients have bilateral juvenile cataracts, but do not have an
association with osteosarcoma. Type II RTS patients have biallelic mutations in the RECQL4
gene, which encodes the RECQL4 DNA helicase (Lu et al., 2020).

B

A

Figure 1: Characteristics of Rothmund- Thomson Syndrome
Rothmund-Thomson Syndrome is characterized by A) sparse hair and eyelashes,
poikiloderma (red erythema on the cheeks) and B) radial ray defects, in this case
resulting in a missing digit.

Images courtesy of Lisa L. Wang, 2016, and are used with permission.
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RECQL4 is one of five human ATP-dependent helicases, all of which are associated
with a predisposition to cancer (Brosh, 2013; Peng et al., 2019). Like other RECQ DNA
helicases, RECQL4 is thought to aid in firing at the origin of replication (Croteau et al.,
2014). Indeed, it has been demonstrated that a depletion of RECQL4 in cells reduces the
frequency of firing at the origin of replication (Thangavel et al., 2010), pointing to replication
as a critical function. RECQL4 also has been shown to function in non-homologous end
joining as a means of double strand break repair (Shamanna et al., 2014). We will build
upon the foundational principle that osteosarcoma can be caused by aberrant DNA
replication and incomplete repair resulting from mutations in RECQL4 by exploring
dysregulted transcriptional pathways in the presence of RECQL4 mutations,
RECQL4 is one member of the RecQ DNA helicase family, with several functions
that are described, below. RECQL4 has been demonstrated to function in the initiation of
DNA replication, DNA damage repair, and maintenance of the integrity of telomere and
mitochondrial DNA (Lu et al., 2017). The N-terminus (1~200 aa) of human RECQL4 shares
homology with the yeast Sld2 protein, which is important for the initiation of DNA replication
(Matsuno et al., 2006; Sangrithi et al., 2005). Human RECQL4 interacts with the DNA
replication licensing factor, MCM10, to mediate the formation of the CMG (Cdc45; Mcm2-7;
GINS) replication complex (Im et al., 2009; Kliszczak et al., 2015; Xu et al., 2009). Since
replication stress causes chromosomal instability in human cells (Lamm et al., 2016),
mutations in RECQL4 could cause replication stress leading to genome instability. RECQL4
also functions in unwinding DNA, making it critical for DNA replication (Brosh, 2013; Chen et
al., 2009). In addition, RECQL4 directly participates in DNA damage repair, including
nucleotide excision repair (NER) for UV DNA damage, base excision repair (BER) for
oxidative DNA damage, and DNA double strand break repair (DSBR) through homologous
recombination (HR) and non-homologous end joining (NHEJ) pathways (Lu et al., 2017).
RECQL4 co-localizes and interacts with the xeroderma pigmentosum group A (XPA) protein
which is required for NER, and UV damage to H1299 and HeLa cells and has been shown
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to result in increased co-immunoprecipitation intensity and co-localization between RECQL4
and XPA (Fan and Luo, 2008). In response to H2O2 induced oxidative stress, RECQL4 is
demonstrated to co-localize with, and stimulate the biochemical activities of
apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1), DNA polymerase β, and flap
structure-specific endonuclease 1 (FEN1). These are several key factors in the BER
pathway, indicating that RECQL4 plays a role in BER in mammalian cells (Schurman et al.,
2009). RECQL4 has also been shown to play a role in NHEJ-dependent DSBR by
interacting with and stimulating the activity of the Ku heterodimer, an important member of
the NHEJ pathway (Shamanna et al., 2014). RECQL4 interacts with p53 and masks the p53
nuclear localization signal, which in turn facilitates p53 mitochondrial localization in
untreated normal human fibroblasts (De et al., 2012), providing a new regulatory mechanism
of p53 activity. In addition, RECQL4 can be recruited to laser-induced double strand breaks
(DSB) by the MRE11 nuclease in the human osteosarcoma U2OS cell line, and is required
for 5’ end resection of DSB, the initial step of HR-dependent DSBR (Lu et al., 2016). In
mammalian cells, RECQL4 also associates with RAD51, a key protein involved in
homologous recombination; thus, a defect in RECQL4 function is expected to result in
defective HR associated genomic instability (Petkovic et al., 2005). Supporting this idea,
karyotype analyses in cells from Recql4-deficient mice show increased aneuploidy and
premature centromere separation (Mann et al., 2005).
RECQL4 is shown to localize in the nucleus during S phase and in the cytoplasm during
G2/M phase (De et al., 2012). In mitochondrial nucleoids, the RECQL4-p53 complex
physically interacts with mitochondrial DNA polymerase (PolyA/B2) in human fibroblasts. It
potentiates its binding to the mitochondrial DNA (mtDNA) control region as demonstrated by
the electrophoretic mobility shift assay (Gupta et al., 2014). Recent studies demonstrate
that RECQL4 is essential for the resolution of DNA: RNA hybrids during replication (Chang
et al., 2020). Also called R-loops, these DNA: RNA hybrids are formed during transcription
and resolve when a wild type RECQL4 associates with the TWINKLE complex. In contrast,
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when RECQL4 is mutated, as is the case in Type II RTS, there is no association with the
TWINKLE complex, the R loops remain, and mtDNA replication is halted (Figure 2). This is
of particular importance because RECQL4 function in mtDNA replication is found to be
essential to prevent cellular transformation in fibroblasts (Kumari et al., 2016). Interestingly,
loss of RECQL4 in the mitochondria of RTS fibroblasts results in decreased mitochondrial
membrane potential and complex V activity, which leads to aerobic glycolysis and cell
invasion (Kumari et al., 2016). However, it is still ambiguous if dysregulation of mitochondrial
integrity by loss of RECQL4 contributes to Type II RTS patient-associated bone
malignancies.

1.4

Rothmund-Thomson Syndrome Models
Historically, Type II RTS associated osteosarcoma has been difficult to study due to

the essential nature of RECQL4 and the rarity of this disease. In mouse models, global
knockouts of Recql4 are embryonic lethal, whereas attempts at knockouts of the helicase
domain do not develop osteosarcoma (Hoki et al., 2003; Mann et al., 2005). While global
knockout of mouse Recql4 targeting exon 5 to 8 causes embryonic lethality (Ichikawa et al.,
2002), inactivation of Recql4 in skeletal tissues has recapitulated some features of RTS,
including skeletal abnormalities and small stature (Lu et al., 2015). Cells from these Recql4
conditional mutant mice display elevated p53 activity (De et al., 2012; Lu et al., 2015), and
the skeletal phenotypes in these mice can be partially rescued by p53 inactivation (Lu et al.,
2015). Conditional Recql4 knockout mice were created and further revealed the essential
role of RECQL4 in bone development and in the genetic interaction between RECQL4 and
p53 in osteogenesis (Lu et al., 2015).
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WT

RECQL4 KO

Internal Deletion

Point Mutation

Figure 2: RECQL4 functions in resolving R-loops
A) Wild type RECQL4 associates with the TWINKLE complex in the mitochondria to resolve
R-loops, thereby promoting continued mtDNA replication. B) In the absence of RECQL4,
mitochondrial R loops persist, leading to persistent transcription, but less mtDNA replication.
C) Internal deletion of RECQL4, often associated with RAPADALLINO but not RTS, results
in increased TWINKLE binding resulting in an abundance of mtDNA replication. D) Point
mutations in RECQL4, often associated with RTS result in less TWINKLE binding and an
accumulation of R-loops. We hypothesize that the increased stress caused by R-loops might
trigger increased transcription of genes that promote ATP production via oxidative
phosphorylation, thereby promoting cell proliferation and survival.

Figure adapted from Chang et al., Scientific Reports, 2020.
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While RECQL4 is necessary for osteoblast development, it is not necessary for bone
homeostasis (Ng et al., 2015). Furthermore, mice that lack Recql4 in osteoblast progenitor
cells demonstrate a decrease in mineral apposition rate and bone formation rate (Ng et al.,
2015), but no increase in osteosarcoma. These results imply that osteosarcoma
susceptibility is most likely triggered by mutant, not null, alleles of RECQL4 in RTS patients.
Taken together, current understanding of RECQL4 allows for the possibility that defective
HR-induced genomic instability might contribute to initiating osteosarcoma development in
RTS patients with RECQL4 mutations. Furthermore, genomic instability, combined with
aberrant mtDNA replication, provides a compelling line of inquiry. Indeed, although the
molecular mechanism of osteosarcomagenesis in RTS remains unclear, genomic instability
due to mutations in RECQL4 is implicated in disease development. Murine models arehave
been helpful in understanding RTS, but have not been shown to replicate osteosarcoma (Lu
et al., 2020), suggesting another model is necessary to study Type II RTS associated bone
malignancies.

1.5

Existing Models of Osteosarcoma
Despite the relative prevalence of osteosarcoma, models to study the pathophysiology

of disease are not abundant. Several cancer-derived cell lines are currently used to study
osteosarcoma, including U20S, G292, SJSA, OHS, SAOS-2, MG-63 and TE85 (Schott et
al., 2020). Over time, it became apparent that in order to make inroads towards new
therapeutic options, new models were necessary. In 2015, orthotopic patient-derived
osteosarcoma xenografts were described as a method to examine the diversity of the
disease and to study recurrent osteosarcoma (Blattmann et al., 2015). Current efforts by the
Children’s Oncology Group and others are underway to continue building the available
osteosarcoma xenograft models, but the conclusions from these studies rely on a robust
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cohort to replicate the genetic diversity observed in the patient population (Roberts et al.,
2019).
Recent discussions indicate that more models of osteosarcoma are critical to better
understand the pathophysiology of osteosarcoma (Schott et al., 2020). Genetically
engineered mouse models with conditional and tissue specific P53 and RB knockouts show
promise in recapitulating disease and metastasis in some cases (Guijarro et al., 2014), but
these models do not capture the heterogenous nature of osteosarcoma, nor do they allow
for investigation of RTS associated osteosarcoma. Previously reported models of LiFraumeni syndrome (LFS) associated osteosarcomagenesis (Kim et al., 2018; Lee et al.,
2015; Zhou et al., 2017) demonstrate that patient-derived induced pluripotent stem cells
(iPSCs) are an appropriate model to study the pathological mechanisms in LFS patients
genetically predisposed to osteosarcoma. Therefore, we sought to establish an induced
pluripotent stem cells (iPSC) model of RTS to address the current need for more varied
models of osteosarcomagenesis,

1.6

Induced Pluripotent Stem Cells
One of the major challenges of studying RTS associated osteosarcomagenesis is the

lack of a model that recapitulates the disease (Lin et al., 2017b). Several attempts at
producing Reql4 deficient mice (Lu et al., 2015; Ng et al., 2015) and other organisms like
drosophila and zebrafish (2017; Wu et al., 2008) fail to recapitulate the osteosarcoma
phenotype and, by nature of the models, are unable to address early transcriptional changes
that lead to osteosarcoma. For example, whole body knockout of Recql4 is embryonic lethal
(Ichikawa et al., 2002) and conditional knockouts of the helicase coding region of Reql4 do
not result in osteosarcoma (Lu et al., 2015; Ng et al., 2015). In this study, we address these
issues by working with induced pluripotent stem cells (iPSC), which were subsequently
differentiated to recapitulate osteosarcoma.
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Landmark studies (Takahashi and Yamanaka, 2006) paved the way for this
investigation by demonstrating how reprogramming somatic cells results in stem cells, called
iPSCs. They described a method to transduce four transcription factors to confer
pluripotency. These factors are added to cultured primary fibroblasts and, over time, dedifferentiated stem cells survive and proliferate. Furthermore, in vitro modeling of human
disease has become possible with these iPSC methodologies (Takahashi et al., 2007) .
Additionally, numerous laboratories demonstrate that PSCs (ESCs and iPSCs) overcome
many limitations found in other model systems and can serve as a relevant model system to
study the etiologies of cancer, including osteosarcoma (in LFS (Lee et al., 2015), Werner’s
Syndrome (Cheung et al., 2014; Shimamoto et al., 2014), Diamond Blackfan Anemia
(Doulatov et al., 2017; Garcon et al., 2013) and Retinoblastoma (Zeng et al., 2016)) (Figure
3B), brain tumors (Duan et al., 2015; Funato et al., 2014), and leukemia (Mulero-Navarro et
al., 2015).
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Chapter Two: Establishing Rothmund-Thomson Syndrome
Induced Pluripotent Stem Cells

Figures and text are partially reprinted from Jewell BE, Liu M, Lu L, Zhou R, Tu J, Zhu D,
Huo Z, Xu A, Wang D, Mata H, Jin W, Xia W, Rao, P, Zhao R, Hung MC, Wang LL, Lee DF.
Generation of an induced pluripotent stem cell line from an individual with a heterozygous
RECQL4 mutation. Stem Cell Res. 2018 October 9; 33: 36-40.
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2.1 Introduction
RECQL4, one of five human RecQ DNA helicases, is known as a guardian of the
genome due to its function in multiple DNA metabolic processes, including DNA replication,
recombination, and repair (L. Van Maldergem, 2016; Lin et al., 2017a). Biallelic mutations in
the RECQL4 gene are responsible for the majority of cases of Rothmund-Thomson
syndrome (RTS), an autosomal recessive disorder characterized by multiple clinical
features, including a poikilodermatous skin rash, small stature, skeletal dysplasias, and a
striking risk for developing osteosarcoma (L. Van Maldergem, 2016; Lin et al., 2017a).
We first reprogrammed fibroblasts from an RTS heterozygous carrier of the RECQL4
mutation c.1878+32_1878+55del24, a 24 base pair deletion in intron 11 of the RECQL4
gene (Figure 3). This mutation results in a shortened intron and is shown to cause aberrant
splicing leading to exon skipping (Colombo et al., 2018; Wang et al., 2002). The iPSCs we
describe here will be useful in characterizing the role of RECQL4 in DNA damage repair and
replication. They also provide the framework for reprogramming iPSCs, which have biallelic
RECQL4 mutations and were derived from patients with osteosarcoma. Furthermore, the
control cell lines described in this chapter are the parent of a patient with Type II RTS and
associated osteosarcoma. The background genetic similarity to the patient is theoretically
50%, providing an ideal control for future experiments.

2.2 Culturing RTS Fibroblasts
Fibroblasts were isolated from a punch biopsy taken from the arm of an individual
with a heterozygous RECQL4 (c.1878+32_1878+55del24) mutation (The Molecular Basis of
Familial Cancer Predisposition Syndromes (IRB# H-7207) Baylor College of Medicine).
These fibroblasts were cultured using high glucose media for less than 10 passages. Then,
they were preserved very carefully after proliferation by dissociating one 10cm dish of
confluent fibroblasts gently with a minimum amount of trypsin (400µL), then subsequently
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freezing in1ml of Cryopreservation media. It is important to note that these cells were not
immortalized or changed in any manner that might have altered their cell signaling prior to
reprogramming.
c.1878+5G>A
c.1878+32_1878+55del
c.1483+25_1483+35del
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Figure 3: RECQL4 mutations associated with Rothmund-Thomson Syndrome

The RECQL4 gene is represented, with the 21 exons marked as boxes and the helicase
region highlighted in blue. Mutations occur across the entire gene and are located in both
introns and exons. The lower inset depicts the heterozygous mutation described, in the intron
11. This mutation was verified in the Family B2 induced pluripotent stem cells by Sanger
sequencing.

The upper portion of this figure was adapted from Van Maldergem et al., Epstein's Inborn
Errors of Development, 2016.
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2.3 Establishing Familial Induced Pluripotent Stem Cells: RECQL4mut/wt
controls
Primary fibroblasts were reprogrammed by the Yamanaka four factors, OCT4, SOX2,
KLF4 and MYC, using the CytoTune-iPS Sendai Reprogramming kit. The emerged iPS
clones were picked and cultured on mouse embryonic fibroblasts (MEF) for approximately
11-15 passages (Figure 4). The iPS clone Family B2 exhibited hESC morphology, which
was evident by cell clusters with a dense, domed center and well-defined borders (Figure 5)
Scale bar, 250 μm). PCR detection of exogenous OCT4, SOX2, KLF4 and MYC in Family
B2 iPSC line verified loss of the Sendai virus and transgenes (Figure 5.B). PCR-based
mycoplasma detection assay further validated that the FCP351G iPSCs were free of
mycoplasma (Figure 5.C).
Short tandem repeat (STR) profiling was performed to determine the cell of origin for
the clonal Family B2 iPSCs. The STR profile of Family B2 clones were identical to that of
Family B2 fibroblasts from which they were derived (Table 1). Immunofluorescence staining
of Family B2 iPSCs demonstrated ubiquitous expression of the pluripotency transcription
factor NANOG and hESC surface markers, SSEA-4 and TRA-1-81 (Figure 6). In addition to
the immunofluorescent staining, Family B2 iPSCs exhibited consistent alkaline phosphatase
surface staining among all colonies, which is indicative of stemness (Figure 5.A).
Examination of pluripotent gene expression by qRT-PCR showed that FCP351G iPSCs
expressed pluripotency genes NANOG, OCT4, SOX2, DPPA4, REX1 and TERT at a level
equal to or greater than H1 hESCs. In contrast, Family B2 fibroblasts, the cells from which
the iPSCs were reprogrammed, did not express these genes (Figure 7). G-band karyotyping
is usually done when repgrogramming iPSCs to examine for any chromosomal
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Day 0
Add Oct-4, Sox-2, Klf-4,
and c-Myc directly to
fibroblasts in Transduction
Media

Fibroblasts

Day 5
Change to
Growth Media
Cells ~50%
confluent

Day 1
Change to
Fibroblast
Media

Passage 1, Day 15

Passage 2, Day 3

Day 7
seed cells
on MEFs

Passage 4, Day 7

Day 8
change to
iPSC media;
replace
every
2 days
for 28 days
Passage 10, Day 3

Scale bar = 100µm

Figure 4: Reprogramming fibroblasts to establish iPSCs

The upper panel summarizes the initial steps in reprogramming, from the starting point of
fibroblast through the generation of initial clones. The bottom panel shows phase microscopy of
Family B2 fibroblasts, then shows the first passage of an emerged clone. It then depicts the
passages at which morphological changes occur until passage 10, at which point stemness was
evaluated.
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Figure 5: Verification of Family B2 induced Pluripotent Stem Cells

A) Phase microscopy and alkaline phosphatase staining depict stem cell morphology
and surface staining indicative of stem cells. B) PCR to test for the Sendai virus
delivery vector and Yamanaka factors demonstrated zero footprint iPSCs. C)
Mycoplasma testing shows the iPSCs are free of the contaminant.
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Table 1: STR analysis

Marker site
AMEL
CSF1PO
D13S317
D16S539
D18S51
D21S11
D3S1358
D5S818
D7S820
D8S1179
FGA
TH01
TPOX
vWA

Family B2
X
10,12
11,12
9,12
12,19
31.2,32.2
15, 16
10,12
9,12
13,14
19,23
6, 9.3
8,11
17,18
Match each other

Family B Fibroblasts
X
10,12
11,12
9,12
12,19
31.2,32.2
15, 16
10,12
9,12
13,14
19,23
6, 9.3
8,11
17,18

Short tandem repeat analysis of Family B2 induced pluripotent stem cells and Family B
fibroblasts, from which the iPSCs were derived, indicate that the iPSCs originate from the
fibroblasts, validating our method of reprogramming.
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Figure 6: Immunofluorescence of Family B2 iPSCs

Staining of individual clones exhibited ubiquitous expression of the pluripotency
markers Nanog, TRA-1-81, and SSEA-4. When merged with the nuclear stain DAPI,
very high reprogramming efficiency can be observed.
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A

B

Figure 7: Characterizing Family B2 iPSCs

A) qRT-PCR shows expression of each of the pluripotency markers at
approximately the same level of hESCs, but significantly different than the
fibroblasts from which they were reprogrammed. B) G-band karyotyping shows a
normal chromosomal spread.
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Endoderm/Epithelium

Mesoderm/Cartilage

Ectoderm/Melanin

Figure 8: Family B2 teratoma

H&E staining of teratoma formed after subcutaneous injection of iPSCs
demonstrate Family B2 iPSCs possess the ability to spontaneously
differentiate into all three germ layers, verifying their stemness.
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abnormalities that may have occurred during reprogramming. Karyotype analysis confirmed
the normal karyotype of the Family B2 iPSCs (Fig 7.B). Teratoma assays then were used,
as they are the gold standard of pluripotency. In this assay, iPSCs were injected
subcutaneously into nude mice without extraneous growth factors to test their ability to
spontaneously differentiate into all three germ layers. Teratoma formation indicated that
Family B2 iPSCs were capable of differentiation into three germ layers, including epithelium
(endoderm), cartilage (mesoderm), and melanin (ectoderm) (Figure 8), confirming their
pluripotency.

2.4 Establishing RECQL4mut/mut Type II RTS Osteosarcoma Patient –
Derived Induced Pluripotent Stem Cells
After establishing iPSCs from Family (control) RECQL4mut/wt cells, we were
encouraged that RECQL4mut/mut fibroblasts from Type II RTS patients could be
reprogrammed, despite the known essential function of RECQL4. Because the available
current models for studying Type II RTS with osteosarcoma are limited, we aimed to
establish a Type II RTS iPSC model in order to contribute to the current body of knowledge
of RTS and RECQL4 mutations. This model is critical for elucidating molecular
pathophysiology due to the specificity of the RECQL4 mutation in osteosarcomagenesis.
First, we describe reprogramming of RTS osteosarcoma patient cells to iPSCs and
subsequent differentiation to osteoblasts, thereby generating a model to study RTS
associated osteosarcoma tumorigenesis.
To dissect the pathological processes of osteosarcomagenesis in Type II RTS, we
sought to develop a Type II RTS induced pluripotent stem cell (iPSC) model that could be
complementary to current mouse and tissue culture models for investigating how RECQL4
mutations contribute to Type II RTS patients’ bone malignancies. We first chose 4 Type II
RTS families in which patients were diagnosed with osteosarcoma. Their corresponding
healthy parents were used as controls (Table 2). These Type II RTS patients possessed
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biallelic mutations in the DNA helicase RECQL4 and developed osteosarcoma at different
ages. Their parents, referred to as Family, had one heterozygous RECQL4 mutation and
remained healthy. These Type II RTS patients possess biallelic mutations in the DNA
helicase RECQL4 and develop osteosarcoma at different ages, whereas their parents,
referred to as Family, with one heterozygous RECQL4 mutation remain healthy.
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Table 2: Patient Samples for iPSC Reprogramming
Fibroblasts iPSCs
FCP-402
RTS-120
FCP-351
RTS-112
FCP-154
FCP-153
FCP-131
FCP-129

Relationship
Family1F-A1,2,3
Father
Family1RTS-A1,2,3 Proband
Family2F-B1,2,3
Mother
Family2RTS-B1,2,3 Proband
No visible Family3clone
Mother
No visible Family3clone
Proband
No visible Family4clone
Mother
No visible Family4clone
Proband

Clinical
description

RECQL4 gene status

Normal
Osteosarcoma
(10.6y)

c.2719C>T/WT

Normal
Osteosarcoma
(10.8y)

c.1878+32_1878+55del24/WT
c.1878+32_1878+55del24/c.15
73delT

Normal
Osteosarcoma
(33.3y)

c.1391-1G>A (IVS7)/WT
c.1391-1G>A
(IVS7)/c.1573delT

Normal
Osteosarcoma
(4.3y)

c.2269C>T/WT

c.2719C>T/c.2719C>T

c.2269C>T/c.1573delT

Listed in this table are both RTS osteosarcoma patients, who possess biallelic RECQL4
mutations, and Family (F) controls, who are parents with a heterozygous RECQL4 mutation,
but do not develop osteosarcoma or other RTS symptoms. Used in this study are set A and
set B, resulting in 12 total iPSC lines.
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Type II RTS and control Family fibroblasts were transduced with the Yamanaka four
factors (NANOG, OCT4, SOX2 and MYC) (Fusaki et al., 2009; Takahashi and Yamanaka,
2006) via the Sendai virus vector as described previously. After cellular reprogramming and
clone selection, two out of four sets successfully generated paired RTS patient/ Family
control iPSCs. The low reprogramming efficiency in RTS and their Family iPSCs implied the
potential role of RECQL4 in cellular reprogramming. These RTS and Family iPSCs exhibited
human embryonic stem cell (hESC) clonal morphology and ubiquitously expressed the
pluripotency transcription factors NANOG and OCT4, as well as the hESC surface antigens,
TRA1-81 and SSEA4 (Figure 9). Consistently, quantitative reverse transcription PCR (qRTqPCR) confirmed the similar expression of NANOG, SOX2, and OCT4 as compared to the
hESC H1 cells (Figure 10). To test the ability of these cell lines to differentiate into all three
germ layers in vivo, teratoma formation assay, again, was performed. Examination via H&E
stained teratoma revealed both RTS and Family iPSCs were capable of differentiating into
ectodermal, endodermal, and mesodermal lineages (Figure 11), confirming their
pluripotency. We further verified the loss of exogenous SeV-OCT4, SOX2, KLF4 and MYC
transgenes by genomic PCR detection and confirmed no detectable SeV transgenes (Figure
12). This suggested that these RTS and Family iPSCs were zero-genetic footprint.
As RECQ family DNA helicases play a critical role in maintaining genome integrity
(Gupta and Schmidt, 2020), the deficiency of these proteins has been associated with
genomic instability, several features of cancer predisposition, and a premature aging
phenotype (Lu et al., 2017; Mohaghegh and Hickson, 2002). To examine the genomic
integrity of these cells, G-band karyotyping was performed in both RTS and Family iPSCs
(Figure 13). Chromosome analyses indicated RTS-A and Family-A iPSCs possessed
chromosomal abnormalities. Both RTS-B and Family-B iPSCs presented as normal
karyotypes. Despite these differences, the phenotype of RTS associated osteosarcoma and
no known familial malignancy held true. We suspect that the abnormal chromosome
deletions in RTS-A and Family-A iPSCs may have occurred from either original fibroblasts or
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the reprogramming process. In addition, lower efficiency in the generation of RTS and
Family iPSCs imply an essential role of RECQL4 in cellular reprogramming. All together, we
generated six RTS and six Family iPSC cell lines, which exhibited chromosomal and sex
diversity, allowing for robust further study.

Figure 9: Immunofluorescence of Patient and Family iPSCs

Phase microscopy of individual clones from representative cell lines exhibited
clonal morphology, defined borders, and dense centers, indicative of stemness.
Immunofluorescent staining using the pluripotency markers Nanog and Oct-4 and
the surface markers TRA-1-81, and SSEA-4, co-stained with DAPI. Each of the
immunofluorescence microscopy showed ubiquitous expression of each of the
pluripotency markers, further indicating stemness and high reprogramming
efficiency.
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Figure 10: qRT-PCR of iPSCs

qRT-PCR assay for pluripotency genes NANOG, OCT4, and SOX2 in RTS and
Family (F) iPSCs. Error bars indicate SEM of triplicates. n=3 biological replicates;
error bars represent ±SEM; statistical significance was determined using one-way
ANOVA followed by Student’s t test (Tukey’s multiple comparison test); ***p< 0.001.
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Figure 11: Teratoma assay
In vivo teratoma formation assay demonstrated RTS and Family iPSCs were
capable of differentiation into all three germ layers, confirming pluripotency. Scale
bar, 200 µm.
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Figure 12: Zero-footprint iPSC generation

PCR detection of SeV genome and transgenes indicated RTS and Family
iPSCs are footprint-free.
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Figure 13: G-band karyotyping of iPSCs

G-band karyotyping of RTS and Family (F) iPSCs showed that set A possess
chromosomal abnormalities, while set B possess normal karyotypes.
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2.5 Generation of Mesenchymal Stem Cells and Their Derived
Osteoblasts
After establishing these RTS and Family iPSC lines, we next sought to utilize these
iPSCs to investigate the pathological mechanisms involved in RTS patients associated bone
malignancies. We first differentiated these iPSCs to mesenchymal stem cells (MSCs) by a
SB-431542 and 7.5% CO2 induced MSC differentiation method (Leyendecker Junior, 2018).
After 60 days of differentiation, cells exhibited the change from clonal morphology to the
elongated and swirling pattern typical of MSCs, shown in the phase microscopy (Figure 14).
These iPSC-derived MSCs were then examined for the presence of typical MSC surface
markers, CD73, CCD44, and CD105. Immunostaining showing high efficiency of CD73,
CCD44, and CD105 expression in SB-431542 and 7.5% CO2 induced MSCs confirmed the
successful differentiation of iPSCs to MSCs.
These well-defined MSCs were further differentiated to osteoblasts, a potential
osteosarcoma cell-of-origin, by a defined osteogenic differentiation method (Lee et al.,
2015). As osteogenic differentiation progressed, MSC morphology shifted from elongated
and swirling to a cobblestone appearance, characteristic of osteoblasts (Figure14). Mature
osteoblasts are capable of forming the bone by depositing minerals and cellular matrix
formation (Capulli et al., 2014). After 24 days of osteoblastic differentiation, positive alizarin
red staining (ARS) of RTS and Family MSC-differentiated osteoblasts indicated successful
osteogenic differentiation (Figure 15). Taken together, each step, from cellular
reprogramming through lineage differentiation, illustrated a model of iPSC-derived
osteoblasts suitable for investigating RTS patient associated bone malignancies.
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Figure 14: Differentiation of Mesenchymal Stem Cells

Immunostaining demonstrated that iPSC-derived MSCs exhibited swirling
morphology (phase) and expressed MSC surface markers CD73, CD44, and
CD105. Scale bar, 100 µm.
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Figure 15: Differentiation of osteoblasts

RTS and Family MSC-derived osteoblasts at early osteoblast stage (Day 15)
and Late osteoblast stage (Day 24) exhibited cobblestone morphology, typical
of osteoblasts. Alizarin red staining (ARS) demonstrated the ability of
differentiated osteoblasts to deposit minerals. Scale bar, 100 µm.

36

Chapter Three: Transcriptional Changes During Osteoblast
Differentiation Reveal Increased Oxidative
Phosphorylation in Type II RTS Patient – Derived Cells

37

3.1 Introduction
Oxidative phosphorylation as a target for treatment has been a topic of particular
interest with respect to cancer treatment for several years (Ashton et al., 2018). Metabolic
reprogramming has long been understood as a hallmark of cancer, but traditionally the focus
has been on glycolytic upregulation (Hanahan and Weinberg, 2000). More recently, the
importance of oxidative phosphorylation has become apparent in many cancer types,
ranging from solid tumor to hematological malignancies (Ashton et al., 2018). Recent
discussions underscore the need for more in-depth investigation into the role of oxidative
phosphorylation in cancer development and progression (Zu and Guppy, 2004). Recently,
metabolic reprogramming has been shown to be critical to tumorigenesis in other cancers
(Bonnay et al., 2020). Interestingly, metastatic osteosarcoma has been shown to be
inhibited by Metformin, mediated by PTEN (Li et al., 2018), emphasizing that the
dysregulation of mitochondrial functions plays a role in osteosarcomagenesis. Although
there is a strong link among oxidative phosphorylation, metabolic reprogramming, and
tumorigenesis, it has largely gone unexplored with regard to osteosarcoma.

3.2 Altered mitochondrial respiratory gene signature in RTS osteoblasts
RTS and Family iPSC-derived cell samples were collected at three different
differentiation stages for RNA-seq analyses in order to gain insight into the underlying
pathological mechanisms involved in RTS associated osteosarcomagenesis. These stages
were: MSCs (day 0), pre-osteoblasts (day 15) and mature osteoblasts (day24).
Transcriptional profiling comparing the RTS and Family cell lines at different differentiation
stages allowed us to interrogate the molecular dysregulation leading to
osteosarcomagenesis in RTS patients. We first used gene set enrichment analysis (GSEA)
to identify enriched Gene Ontology biological processes (GO_BP) in both RTS and Family
samples. This was done in order to determine the nature of these discrete transcriptional
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profiles (Figure 16.A). The heatmap of summarized enrichment GO_BP demonstrated that
many mitochondrial energy production functions were enriched in RTS osteoblasts. These
pathways included ATP synthesis coupled electron transport, mitochondrial respiratory
chain complex assembly, NADH dehydrogenase complex assembly, and oxidative
phosphorylation (Figures 16.B). Interestingly, these pathways were increasingly enriched as
differentiation progressed, indicating that the alteration of transcriptome profiling related to
ATP production occurred in osteoblast lineages. In contrast, GO_BP analyses revealed
significantly decreased enrichment of skeletal development pathways (e.g., bone
morphogenesis, bone development, cell matrix adhesion, extracellular matrix assembly,
etc.) in the RTS patients (Figure 16.B). This supports the clinical observation that RTS
patients show small stature and skeletal abnormalities.
Complementary KEGG pathway analyses also were performed. As a result, it
became clear that oxidative phosphorylation is a compelling pathway for further interrogation
as an important regulator of increased energy that may contribute to RTS patient associated
bone malignancies (Figure 17). Interestingly, the TCA cycle pathway also was upregulated
in RTS osteoblasts, providing a potential substrate for an increase in electron transport
chain (ETC) activity (Figure17.B). These findings were validated further by Reactome
biologic pathways and process analysis showing elevated transcription in genes related to
respiratory electron transport and respiratory electron transport ATP synthesis by
chemiosmotic coupling and heat production by uncoupling proteins (Figure 18). In addition
to impaired skeletal development pathways found in RTS osteoblasts, KEGG pathway and
Reactome analyses also revealed that reduced TGFβ, NOTCH3 integrin signaling pathways
as well as WNT, a key bone morphogenesis regulator pathway, were impaired in RTS
osteoblasts (Figure 18). A decrease in skeletal development pathways was observed
consistently in the osteoblast transcriptional signatures in the osteosarcoma-prone genetic
disorder, LFS (Lee et al., 2015).
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Figure 16: GSEA analyses identify enriched gene ontology biological processes
(GO_BP) in RTS and Family osteoblasts.

A) 7525 gene sets were used in GO_BP analysis. A positive NES (green) represents
GO_BP gene sets enriched in the transcriptome of Family osteoblasts; in contrast, a
negative NES (orange) represents GO_BP gene sets enriched in the transcriptome of RTS
osteoblasts. Enriched gene sets were selected based on statistical significance (normalized
p-value < 0.05 and FDR q-value < 0.25). B) Heat maps depict the significantly altered
GO_BP found in RTS MSCs, pre-osteoblasts, and osteoblasts as compared to Family
counterparts. C) GSEA leading edge analysis shows the overlapping enriched gene sets in
RTS and Family osteoblasts. D) Mitochondrial ATP production related GSEA GO_BP
results showed upregulated ATP synthesis coupled electron transport, mitochondrial
electron transport NADH to ubiquinon, mitochondrial respiratory chain complex assembly,
and oxidative phosphorylation) in RTS mature osteoblasts.
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Figure 17: KEGG pathway analyses reveal enriched pathways in RTS and Family
osteoblasts

A) 183 pathways were used in KEGG pathway analysis. Positive NES (blue) represents
pathways enriched in the transcriptome of Family osteoblasts; negative NES (red) represents
pathway enriched in the transcriptome of RTS osteoblasts. Enriched pathways were selected
based on statistical significance (normalized p-value < 0.05 and FDR q-value < 0.25). B) Right
heat map shows the significantly altered pathways found in RTS MSCs, pre-osteoblasts, and
osteoblasts as compared to Family. C) The representative enriched KEGG pathways, including
oxidative phosphorylation, peroxisome, and WNT signaling pathways enriched in RTS or Family
osteoblasts are shown.
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Figure 18: Reactome analysis confirms RTS increased metabolism via electron
transport in mitochondria.

Reactome analysis demonstrated that multiple canonical pathways were enriched in
RTS and Family MSCs, pre-osteoblasts and osteoblasts, respectively.
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In addition to pathway analysis, we also sought to explore the nature of
chromosomal predisposition to osteosarcoma. Alterations of the genome in osteosarcoma
patients is well understood (Lindsey et al., 2017). Alterations identified by Cytogenetic
Region Enrichment Analysis (CREA) (Walkley et al., 2008) reveals that in RTS patients,
several cytogenetic regions, which are indicated as important for osteosarcoma-promoting
cytogenetic rearrangement, are highly upregulated in RTS day 24 osteoblasts in comparison
to Family (Figure 19). To further explore the potential cancer-related pathways contributing
to osteosarcomagenesis in RTS patients, we examined the altered oncogenic signatures in
RTS osteoblasts in order to further explore the potential cancer-related pathways
contributing to osteosarcomagenesis in RTS patients. We discovered that neoplastic
pathways involving MYC (Chen et al., 2018) and EIF4E (Qi et al., 2019) were upregulated,
while the p53 tumor suppressor pathway was downregulated (Figure 19.A). Furthermore, we
analyzed the enrichment of transcription factor targets (TFT) to explore the potential RTSassociated gene signature triggered by transcription factors. We observed upregulated AP1,
NRF2, ELK1, prognostic of prostate cancer disease reoccurrence (Pardy et al., 2020). We
also found NRF2 targets but downregulated FOXO1, a potential tumor suppressor
regulating gluconeogenesis (Gross et al., 2008) targets in RTS osteoblasts (Figure 19.B).
Taken together, our transcriptome analyses of RTS osteoblasts emphasized that the
elevation of mitochondrial energy production and oncogenic signature, as well as a
decrease in tumor suppression pathways, may contribute to osteosarcomagenesis in RTS
patients.
We next validated the upregulation of oxidative phosphorylation genes in RTS
osteoblasts. We found that NDUF7, NDUFB1, NDUFB2, and NDUFS8, which are thought to
be involved in both the accessory and catalytic subunits of mitochondrial respiratory
complex I (Formosa et al., 2018), were upregulated in RTS osteoblasts as compared to the
Family osteoblasts in both paired sets (Figure 20). Importantly, mitochondrial ATP
production pathways (e.g., oxidative phosphorylation, respiratory electron transport chain,
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TCA cycle, and mitochondrial respiratory complex assembly) were activated significantly in
sporadic osteosarcoma as compared to normal osteoblasts and bone tissues (Figure 21).
As a result of these observations, our methodic transcriptome analyses led us to
hypothesize that the elevated complex I enzymatic activity of RTS osteoblasts may play a
critical role in osteosarcomagenesis in RTS patients.
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Figure 19: CREA analysis demonstrates chromosomal signature predisposed
to osteosarcoma in Day 24 osteoblasts

Cytogenetic analysis of day 24 RTS osteoblasts compared to Family control
osteoblasts, Day 17 Li Fraumeni Syndrome (LFS) iPSC derived osteoblasts
compared to wild type (WT) osteoblasts, human osteosarcoma (OS) versus
differentiated healthy osteoblasts (OB), synovial sarcoma (SS) and muscle
demonstrate a pattern of genomic rearrangements that is most pronounced in RTS
osteoblasts.
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Figure 20: Additional pathway analyses provide pathways that may
contribute to tumorigenic potential.

A) Oncogenic signature revealed specific gene-disturbed transcriptome signatures
were enriched in either RTS or Family MSCs, pre-osteoblasts and osteoblasts. B)
Transcription factor target (TFT) analysis of the regulatory target gene sets
revealed potential dysregulated transcription factors in both RTS and Family
MSCs, pre-osteoblasts and osteoblasts.
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Figure 21: Complex I genes are significantly upregulated in RTS patient day
24 osteoblasts compared to Family controls

Individual genes (NDUFA7, NDUFB1, NDUFB2, and NDUFS8) that compose
complex I of the electron transport chain were upregulated significantly in RTS
osteoblasts. n=3 biological replicates; error bars represent ±SEM; statistical
significance, which was determined using one-way ANOVA followed by Student’s
t test (Tukey’s multiple comparison test); *p< 0.05; **p< 0.01.
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Figure 22: GO-BP analysis shows upregulation in sporadic osteosarcoma
compared to healthy bone

A) Network visualization of gene sets enriched in osteosarcoma compared with normal
bone and osteoblasts (p value <0.05, FDR q value <0.1) indicates that GO_BP involved
in DNA repair, chromatin regulation, cell cycle, and mitochondrial ATP production and
repair were enriched in osteosarcoma. The number of enriched genes in each GO is
displayed as node size, with closer distance between nodes representing increased
overlap between genes in ontologies. Enriched gene sets in osteosarcoma are
displayed in red and enriched gene sets in bone and osteoblasts in blue. B)
Representative enriched gene sets (ATP synthesis coupled electron transport and
respiration electron transport chain) involved in mitochondrial ATP production were
consistent with those observed in RTS osteoblasts.
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3.3 Characterization of Mitochondrial Complex I, II, III, and IV activities in
RTS Osteoblasts
We systematically examined enzymatic activity through mitochondrial complexes,
including complex I, complex I and III, complex II, complex II and III, complex V, and citrate
synthase enzyme activity to explore the biochemical activity of the electron transport chain
(Figure 22). We found that RTS osteoblasts significantly increased the mitochondrial
complex I activity, but not that of complex II, III, or IV. Mitochondrial complex I is of particular
importance as it is the first in the electron transport chain, establishing the electrochemical
gradient necessary for ATP production (Brandt, 2006). In agreement with mitochondrial
enzymatic activity assays, transcriptome results showed significant increase in mitochondrial
complex I NDUFA7A, NDUFB1, NDUFB2, NDUFS8 mRNA expression (Figure 20). These
findings led us to conclude that increased activity through mitochondrial complex I was the
result of the increased transcription of complex I genes.

49

Figure 23: RTS patient osteoblasts have increased enzyme activity through
complex I

Enzyme activity of complex I was increased in RTS osteoblasts. Enzyme activity of
complexes I and III, complex II, complexes II and III, complex V, and citrate synthase
showed no significant difference between Family and RTS osteoblasts, leaving
complex I as the only component of the electron transport chain with upregulated
activity. n=3 biological replicates; error bars represent ±SEM; statistical significance
was determined using one-way ANOVA following by Student’s t test (Tukey’s multiple
comparison test); *p< 0.05.
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3.4 Characterization of Oxidative Phosphorylation in RTS Osteoblasts
Seahorse assays are a robust and sensitive methodology to measure changes in
oxidative phosphorylation and glycolysis via measurements of oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR) (Zhang and Zhang, 2019). Therefore, we
applied Seahorse metabolic assays to explore oxidative phosphorylation and cellular
metabolic flux of RTS osteoblasts. We found that RTS osteoblasts had increased OCR
compared to Family cells (Figure 23). The basal respiration of RTS osteoblasts was
increased significantly as compared to Family osteoblasts, indicating that RTS osteoblasts
have an increased ability to produce ATP. In comparison with Family osteoblasts, RTS
osteoblasts also had significantly increased proton leak under normal culture conditions.
This indicated an increased ability to create the proton gradient across the mitochondrial
inner matrix that is essential for ATP synthase activity. Indeed, RTS osteoblasts specifically
increased all ATP linked respiration and maximal respiration. These findings led us to
conclude that RTS osteoblasts produce significantly more ATP via oxidative
phosphorylation.
RTS osteoblasts also retained significantly more spare respiratory capacity through
increased activity in complex I. In contrast, both RTS and Family osteoblasts had similar
non-mitochondrial respiration (Figure 24), suggesting that mitochondria associated oxidative
phosphorylation was the only cause of increased oxygen consumption rate. We validated
our findings in distinct RTS osteoblasts with different RECQL4 mutations to test if the
increased oxygen consumption rate was universal. We observed a similar trend in increases
of OCR (Figure 23), maximal respiration, and spare respiratory capacity but no difference in
non-mitochondrial respiration in RTS osteoblasts (Figure 25).
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Osteoblasts are shown to be largely reliant on glycolysis for ATP production during
bone morphogenesis (Lee et al., 2017). Therefore, we next compared extracellular
acidification rates (ECAR) to assay for glycolysis function in RTS osteoblasts. We found that
RTS osteoblasts shifted away from glycolysis toward oxidative phosphorylation as a means
of ATP production (Figure 26). Also, RTS osteoblasts had significantly decreased maximal
ECAR (Figure 26). Consistent with the OCR result, this finding indicated that RTS
osteoblasts had little reliance on glycolytic metabolism. Taken together, these OCR and
ECAR data demonstrated that RTS osteoblasts had increased ATP production, specifically
through oxidative phosphorylation and had decreased glycolysis compared to Family
osteoblasts.
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Figure 24: Seahorse assays show increased oxygen consumption rate in RTS
Patients

Seahorse assays indicated increased oxygen consumption rate, which is a measure
of oxidative phosphorylation, in RTS osteoblasts. n=3 biological replicates; error bars
represent ±SEM.
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Figure 25: Seahorse assays revealed increase in mitochondrial respiration in
RTS Patient A

Individual calculations of basal respiration, proton leak, ATP-linked respiration,
maximal respiration, and spare capacity were significantly upregulated in RTS
osteoblasts as measured by Seahorse assay. Non-mitochondrial respiration, which is
not attributed to oxidative phosphorylation, showed no significantly difference
between Family and RTS osteoblasts. n=3 biological replicates; error bars represent
±SEM; statistical significance is determined using one-way ANOVA following by
Student’s t test (Tukey’s multiple comparison test); **p< 0.01; ***p< 0.001
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Figure 26: Seahorse assays revealed increase in mitochondrial respiration in
RTS Patient B

Individual calculations of maximal respiration, and spare capacity were significantly
upregulated in independent RTS osteoblasts as measured by Seahorse assay.
Basal respiration, proton leak, and ATP-linked respiration trend towards increased
rates, consistent with set A. Non-mitochondrial respiration, which is not attributed to
oxidative phosphorylation, was not significantly different between Family and RTS
osteoblasts. n=3 biological replicates; error bars represent ±SEM; statistical
significance is determined using one-way ANOVA following by Student’s t test
(Tukey’s multiple comparison test); *p< 0.05.
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Figure 27: Seahorse assays demonstrate less reliance on glycolysis in RTS Patients
than Family osteoblasts

Seahorse assays showed decreased extracellular acidification rate in RTS osteoblasts,
which is a measure of glycolysis. Individual calculations of basal extracellular acidification
rate and maximal acidification rate were decreased significantly in RTS A osteoblasts,
indicating that RTS osteoblasts rely on oxidative phosphorylation for ATP production.
Maximal acidification rate was decreased significantly in RTS B osteoblasts indicating RTS
osteoblasts rely on oxidative phosphorylation for ATP production. Basal respiration was not
different significantly, but trends toward decreased extracellular acidification rate in RTS
osteoblasts. n=3 biological replicates; error bars represent ±SEM; statistical significance
was determined using one-way ANOVA followed by Student’s t test (Tukey’s multiple
comparison test); *p< 0.05.
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Chapter Four: Targeting Complex I to Reverse Increased
Reliance on Oxidative Phosphorylation in Osteoblasts
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4.1 Introduction
In this study, we utilized non-biased transcriptome analyses of Type II RTS iPSCderived osteoblasts, determined the pathological pathways involved in Type II RTSassociated bone malignancies, and then set out to explore a treatment strategy for Type II
RTS patients with osteosarcoma.
Oxidative phosphorylation inhibitor IACS-070759 shows a potential antineoplastic
activity by binding to and inhibiting mitochondrial respiratory complex I of the electron
transport chain, thereby selectively inhibiting cells replying on complex I function (Molina et
al., 2018; Vangapandu et al., 2018). IACS-070759 robustly suppresses proliferation and
induced cell death in tumor cells reliant on oxidative phosphorylation. It is currently being
evaluated in in phase I clinical trials in acute myeloid leukemia (AML) and solid tumors
(Molina et al., 2018). As hyperactivated mitochondrial complex I function in RTS osteoblasts
meets their increased demands for energy, we tested whether mitochondrial complex I is a
cancer vulnerability for RTS osteoblasts, and whether IACS-070759 is capable of serving as
a therapeutic drug for RTS patients with bone malignancies.

4.2 Inhibition of Oxidative Phosphorylation via Complex I
First, we examined the effect of IACS-010759 on ATP production via oxidative
phosphorylation in RTS osteoblasts using the Seahorse assay. RTS osteoblasts showed
decreased OCR, indicative of decreased oxidative phosphorylation upon IACS-010759
treatment (Figure 27). RTS osteoblasts had significantly decreased maximal respiration,
ATP-linked respiration, and spare capacity to produce ATP (Figure 27). Similar results were
validated using another RTS osteoblast line which showed decreased oxidative
phosphorylation (Figure 27), with significantly reduced maximal respiration, ATP-linked
respiration, and spare respiratory capacity (Figure 27). This indicated inhibition of complex I
via specific inhibition by IACS-010759.
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Figure 28: Treatment with Complex I Inhibitor IACS-010759 decreases
oxidative phosphorylation in RTS Patients

Oxygen consumption rate showed reduced ATP lined respiration, maximal
respiration, and spare capacity in RTS osteoblasts after 100 nM IACS-010759
treatment. Time course of the Seahorse experiment demonstrated that
differences in OCR were most apparent after addition of FCCP, which measure
the maximum potential of ATP production through the electron transport chain.
n=3 biological replicates; error bars represent ±SEM; statistical significance was
determined using one-way ANOVA followed by Student’s t test (Tukey’s multiple
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IACS-010759 is common to RTS treated osteoblasts, irrespective of the specific
RECQL4 mutation. Therefore, we asked if IACS inhibition selectively suppressed RTS
osteoblast growth, as compared to Family controls. Cell proliferation assays demonstrated
that IACS-010759 had a limited effect on Family osteoblast cell proliferation but strongly
inhibited RTS osteoblast cell growth (Figure 28). Overall, these data demonstrated that
oxidative phosphorylation in RTS osteoblasts was upregulated specifically through complex
I. Furthermore, we showed that it was possible to directly target that upregulation in complex
I activity by inhibition with IACS-010759 and this inhibition was specific for RTS osteoblasts,
sparing healthy Family osteoblasts. These results not only demonstrated that the inhibition
of complex I was sufficient to abrogate upregulated levels of maximal respiration in RTS
osteoblasts, but also emphasized the specificity of IACS-010759 to treat the increased
oxidative phosphorylation characteristic of RTS osteoblasts.
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Figure 29: IACS-010759 specifically inhibits RTS Patient osteoblasts

IACS-010759 selectively inhibited RTS osteoblast proliferation. Cell proliferation
assays after treatment with 100 nM IACS-010759, a specific complex I inhibitor,
showed growth inhibition of RTS osteoblasts but little effect on Family osteoblasts.
n=3 biological replicates; error bars represent ±SEM; statistical significance was
determined using one-way ANOVA followed by Student’s t test (Tukey’s multiple
comparison test); ***p< 0.001.
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4.3 Transcriptional Changes After Complex I Inhibition
We next examined the transcriptional changes in RTS osteoblasts upon IACS010759 treatment in order to shed light on the effect of IACS-010759 in halting RTS
osteoblast proliferation. A scatter plot gene expression comparison between IACS-010759
and DMSO treated RTS osteoblasts demonstrated upregulations of long non-coding RNA
H19 and numerous ribosome proteins, including RSP27, RPL11, RPL32, RPL35A, and
RPL11 (Figure 29). Interestingly, H19 was found to function as a tumor suppressor to
promote osteogenesis and inhibit osteosarcomagenesis in LFS osteoblasts and
osteosarcoma (Lee et al., 2015). This provides a potential pharmacological mechanism to
explain IACS-010759-mediated growth suppression effects. It is important to note that
ribosome protein gene mutations are commonly found in osteosarcoma-prone DiamondBlackfan Anemia (DBA) patients (Lin et al., 2017b). Upregulation of ribosomal proteins and
ribosome biogenesis by IACS-010759 could reverse RTS associated oncogenic properties
by promoting translation of tumor suppressors and osteoblast differentiation programming. A
KEGG pathway analysis of significantly upregulated genes IACS-010759-treated RTS
osteoblasts further validated the importance of the upregulation of the ribosome pathway
(Figure 30).
In contrast, the downregulation of cell cycle process (e.g., EPGN, EREG, GPSM2,
etc.) and MAP kinase pathway (STK39, HGF, GHR, etc.) was observed in IACS-010759treated RTS osteoblasts (Figure 30). Enrichr-based GO_BP analysis of differentially
expressed genes (>1.5 fold changes) between DMSO and IACS-010759-treated RTS
osteoblasts demonstrated an increase in protein targeting, T cell mediated cytotoxicity, and
protein translation; whereas there was a decrease in cell cycle processes and MAP kinase
activity in IACS-010759-treated RTS osteoblasts (Figure 30). It is important to note that the
MAP kinase pathway is shown to upregulate cell lifespan and proliferation of RTS fibroblasts
(Davis et al., 2013). In summary, our well-ordered transcriptome analyses provided the
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potential pharmacological mechanisms of IACS- 010759-mediated cell growth inhibition in
RTS osteoblasts.

Figure 30: Transcriptional changes after IACS-010759 implicate important
osteosarcoma-related genes

Scatter plot indicated the marked difference of transcripts between DMSO and 100
nM IACS-010759-treated RTS osteoblasts. H19 and numerous ribosomal protein
genes were upregulated but MAP kinase pathway and cell cycle related genes
were downregulated upon IACS-010759 treatment.
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Figure 31: IACS-010759 causes transcriptional changes that promote healthy
cellular function

Representative IACS-010759-influenced GO_BP, including protein targeting to
membrane, translational initiation, positive regulation of MAP kinase activity, and
positive regulation of cell cycle processes.
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Figure 32: IACS-010759 causes transcriptional changes that indicate reversal
of tumor promoting pathways associated with RTS osteoblasts

GO_BP analysis indicated dysregulated pathways in RTS osteoblasts upon IACS010759 treatment. IACS-010759 activated protein targeting, T cell mediated toxicity,
and protein translation related biological processes, but inhibited MAP kinase and
cell cycle processes in RTS osteoblasts.
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2.5

Chapter Five: Discussion
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5.1 Modeling RTS associated bone malignancies using iPSC-derived
osteoblasts
In this study, we established RTS iPSC disease models from RTS patients with
compound heterozygous RECQL4 mutations and their parental controls with a heterozygous
RECQL4 mutation. Thus far, studies of RECQL4 mutations in murine models have not been
shown to recapitulate the changes that promote osteosarcoma. Other models of sporadic
osteosarcoma focus on fully developed tumors, which may be preselected for
chemoresistance.
The advantages of this disease platform lie in the genetic specificity with which we
dissect the impact of RECQL4 mutation on RTS associated pathological consequences,
such as defective osteogenesis and osteosarcomagenesis. Family-derived iPSCs share
50% genetic fidelity to their child, who are RTS patients. By utilizing these paired Family/
RTS sets, we can specifically interrogate the question of RECQL4 contribution to the
processes that promote osteosarcomagenesis. In addition to the resources we established
in MSCs and osteoblasts, RTS and Family iPSCs are capable of being differentiated into
other germ layers. Differentiation of iPSCs to other tissues might allow for investigation of
the role of RECQL4 in other aspects of Rothmund-Thomson Syndrome, indicating their
potential use to study other disease features of RTS including cataracts, poikiloderma, and
abnormal dentition. Although our model does not recapitulate an osteosarcoma tumor,
osteoblasts differentiated from RTS iPSCs provide a model of osteosarcomagenesis that is
complementary to other models of osteosarcoma.
The iPSC-derived model of osteosarcomagenesis, and associated controls, provide
an ideal model to test potential new therapeutics. In this work, we utilized the disease in a
dish platform to test the efficacy of the complex I inhibitor, IACS-010759. In a similar way,
we provide an ideal model for use in testing other potential therapeutics and show benefits
in using the iPSC derived model for drug testing in general.
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5.2 Increased ATP Production via Oxidative Phosphorylation
Previous studies found that increased rates of metabolic function caused the rate of
bone formation to increase (Guntur et al., 2014). This is consistent with osteosarcoma, as it
is a tumor of uncontrolled bone formation (Lindsey et al., 2017). In our study, we examined
the dysregulated pathways using multiple gene set categories, including GO_BP, KEGG
pathway, Reactome, oncogenic signature, and TFT. These system analyses pointed to the
same culprit of increased metabolism: oxidative phosphorylation. Recent reports of other
cancer types, such as leukemias and lymphomas, as well as for solid cancers like
pancreatic ductal adenocarcinoma, oxidative phosphorylation subtype melanoma, and
endometrial carcinoma, have established the importance of increased oxidative
phosphorylation in tumor formation and progression (Ashton et al., 2018). Here, we
demonstrated increased transcription of oxidative phosphorylation associated genes in RTS
osteoblasts. For example, ATP synthesis coupled electron transport, electron transport
chain, and the TCA cycle (Figure 16) were all indicative of reliance on oxidative
phosphorylation. Electron transport pathways detail the upregulation of genes that are vital
for the creation of the electrochemical gradient necessary for proton pumping through the
inner mitochondrial membrane matrix that allows for conversion of ADP to ATP. In order to
feed the electron transport chain with NADH, which is reduced to free H+ in the first step of
creating the electrochemical gradient, the TCA cycle may produce additional NADH. It would
be interesting to explore the amount of NADH and other TCA cycle substrates, like FADH,
that are produced in the RTS osteoblasts and other cell types, which could be derived from
RTS iPSCs and are relevant to RTS pathology.
The maximal amount of ATP production in bone cells is consistent with increased
osteoblast energy, necessary for tumor formation. It is important to note that in our study,
increased ATP production did not result in upregulation in differentiation in the RTS
osteoblast; in contrast, differentiation was downregulated in RTS cells, suggesting that
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metabolic ATP production is not an osteogenic promoter. Additionally, increased production
of NAD+ through complex I has been shown to immortalize neural tumor cells (Bonnay et
al., 2020). Here, we showed this exact phenomenon in osteoblasts. The increased activity of
complex I was a direct measure of reduction of NADH to NAD+ (Figure 22). Furthermore, it
was shown that an increase of oxidative phosphorylation was essential for cell
immortalization. Bonnay and colleagues speculated that NAD+, which is a PARP co-factor
could play a role in genome stability and cell fate (Bonnay et al., 2020). Therefore, we would
underscore the need for more exploration of these interactions, especially given that
RECQL4 interacts with PARP-1 in the nucleus (Woo et al., 2006).
Bonnay and colleagues, also showed that this switch to oxidative phosphorylation
was important for tumors at stages beyond initiation (Bonnay et al., 2020). Our study,
comparing osteosarcoma tumors and healthy osteoblasts/ bone (Figure 21), showed that, at
a transcriptional level, oxidative phosphorylation was upregulated in osteosarcoma tumors.
This indicates that our findings with regards to osteosarcomagenesis may be important for
osteosarcoma tumor metabolism, in general. It also underscores the appropriateness of
RTS as a model of sporadic osteosarcoma (Lu et al., 2020).
It has been reported that an increase in RECQL4 protein leads to an accumulation of
R-loops, thereby decreasing oxidative phosphorylation in HEK293 cells with a RECQL4
mutation lacking the p32 binding domain (Chang et al., 2020). In our study, RECQL4
mutations led to decreased mtDNA replication due to increased R-loop intermediates. While
it will be necessary to undertake further studies to understand the role of RECQL4 in RTS
associated osteosarcoma, we provide, here, the basis for exploring the role of RECQL4 in
mitochondrial processes. Taken together with the aforementioned studies, an exploration of
RECQL4 in mitochondrial DNA replication in RTS derived osteoblasts is an important
avenue for future study. Given these two findings and our own conclusions of increased
oxidative phosphorylation, one might speculate that the mutant RECQL4 found in RTS
patient cells results in stalled R loop resolution, which is needed for translation of mtDNA. It
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is of particular relevance to this study as seven of the 44 genes necessary to encode
complex I are encoded in mitochondrial DNA (Vartak et al., 2015).

5.3 Targeting Complex I Upregulation with IACS-010759
We sought to explore if inhibition of mitochondrial complex I can be a therapeutic
treatment for RTS osteosarcoma based on our thorough transcriptional and biochemical
studies of oxidative phosphorylation in RTS osteoblasts. IACS-010759 is a complex I
inhibitor specific for the ND1 subunit, blocking the intermembrane transport of H+ (Molina et
al., 2018). It is currently in phase I clinical trial for the treatment of relapsed lymphoma and
metastatic solid tumor cancers. In our study, we demonstrated its efficacy in specifically
inhibiting oxidative phosphorylation and cell proliferation capability of RTS osteoblasts
(Figure 28). We performed RNA-seq to analyze RTS osteoblasts’ transcription upon IACS010759 treatment in order to better understand the effects of IACS-010759 on gene
expression in RTS osteoblasts. It is interesting that IACS-010759 upregulates the
expression of ribosomal protein genes such as RSP27, RPL11, RPL32, RPL35A, and
RPL11, which are known to be mutated in osteosarcoma-prone Diamond-Blackfan Anemia
patients (Chae et al., 2014; Choesmel et al., 2008; Lin et al., 2017b). It is possible that the
homeostasis of ribosomal biogenesis is essential to maintain the survival of RTS
osteoblasts. Furthermore, H19 functioning as an osteogenic promoter and tumor suppressor
was upregulated upon IACS-010759 treatment. This implies that IACS-010759 may indicate
a shift from a tumorigenic, undifferentiated profile back towards normal osteoblast
differentiation. Downregulation of the MAPK pathway and cell cycle were observed, which
has been reported to increase cell life span and proliferation in RTS fibroblasts (Tivey et al.,
2013).

5.4 Implications of this Study
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We have shown that abnormal upregulation of oxidative phosphorylation was the
dominant source of ATP necessary for osteosarcomagenesis in Type II RTS patients.
Inhibition of complex I was sufficient to abrogate the increased oxidative phosphorylation
and cell proliferation of Type II RTS osteoblasts. Taken together, our Type II RTS iPSC
disease platform and targeting of complex I provided a therapeutic target for osteosarcoma
treatment, addressing a great need for Type II RTS osteosarcoma patients, and sporadic
osteosarcoma patients, as a whole.
In summary, our study utilized a RTS iPSC disease platform to dissect the
pathological mechanisms involved in RTS associated bone malignancies. Transcriptome
analysis revealed upregulation of genes involved in oxidative phosphorylation, especially
mitochondrial complex I. Seahorse assays validated upregulation of oxidative
phosphorylation in RTS osteoblasts. The upregulation was targetable in a specific and
clinically relevant manner, using IACS-010759. This study demonstrated a targetable
molecular pathogenesis of osteosarcoma and a clinically relevant treatment option for RTS
patients.
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Chapter Six: Methods
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6.1 Culture of RTS and Family Fibroblasts
Fibroblasts were obtained from RTS patients and their biological parents via a punch
biopsy of the arm (IRB #H-7207, Baylor College of Medicine). The primary fibroblasts were
cultured in fibroblasts culture media (DMEM/F-12 supplemented with 10% FBS, 100 U/ml
Penicillin/Streptomycin (P/S), and 1% GlutaMAX supplement). Fibroblasts were maintained
in a CO2 incubator (37°C, 5% CO2, and 95% humidity). Fibroblasts used for cellular
reprogramming were cultured less than 10 passages.

6.2 Reprogramming fibroblasts to iPSCs
Confluent fibroblasts in healthy condition were transduced with Sendai virus
containing the Yamanaka four factors OCT4, SOX2, KLF4, and MYC using the CytoTune iPS 2.0 Sendai Reprogramming Kit (Invitrogen). Cells were cultured in transduction media
(4 ml reprogramming fibroblast media and 80µl each of OCT4, SOX2, KLF4, and MYC) for
24 hr. After, media were changed to reprogramming culture media (500ml DMEM, 10 ml
FBS, 5ml non-essential amino acid solution (100X), and 3.5µl β-mercaptoethanol). Cells
were cultured in this media for five days, then the media were changed to fresh
reprogramming culture media. On Day 6, mouse embryonic fibroblasts (MEF) were seeded
from frozen cells and cultured in DMEM, supplemented with 10% FBS and 1x P/S for one
day. On day 7, media were removed from MEFs and transduced cells were seeded on
MEFs in growth media after being dissociated using Accutase cell detachment solution for
approximately 5 min at 37°C. On day 8, the media were changed to iPSC media (Knockout
DMEM, 10% Knockout serum, 10ng/µL BFGF, 10ng/µL PDGFAB, 1% non-essential amino
acids, and 0.000007% β mercaptoethanol). Cells were cultured for 28 days and the media
were changed every other day. At day 28, individual iPSC clones were picked using a P200
pipette tip, then subcultured on fresh MEFs for 15 days. iPSCs were then dissociated with
Accutase cell detachment solution and passaged onto 6-well plates coated with Matrigel for
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30 min in iPSC media. After one day, the media were changed to BREW media with XF
supplement. Clones that successfully formed colonies were passaged 10 times in the same
manner described above to ensure removal of the Sendai virus.

6.3 Differentiating Mesenchymal Stem Cells
Cells were differentiated based on the protocol described (Lian et al., 2007).
Passage 10 or later iPSCs that were verified by RT-PCR and immunofluorescent staining
were plated on MEFs for two weeks until 80% confluent. At this point, cells were dissociated
using Accutase, then centrifuged at 1,100 rpm for 5 min. Cells were resuspended in MSC
induction media (DMEM with 10% Knockout Serum, 20ng/mL BFGF, 10ng/µL
SB431542,3.5µL β-mecaptoethanol, and 20ng/ mL), then plated at 1:3 dilution on plates
coated with gelatin for 5 min. Media were changed every day for 14 days, then changed
every two to three days for a total of two times per week, leaving about 500µL in the dish,
each time. After cell morphology changed from clusters to elongated/ spindle-like, cells were
split. Cells were dissociated with trypsin for 3-5 min, resuspended in DMEM, then
centrifuged, as before. Cells then were incubated for several days to proliferate. Once cells
reached 80% confluency, they were split again to 6-well plates for characterization and
propagated in MSC media (DMEM with 10% FBS, 1% L-glutamine, and 1% Penicillin and
Streptomycin).

6.4 Differentiating Osteoblasts
Osteogenic differentiation was carried out based on previously described protocols
(Barberi et al., 2005; Lee et al., 2015). MSCs were split then passaged at a density of 3x 105
cells/per well of a 6 -well dish in osteoblast differentiation media (αMEM supplemented with
10mM β glycerol phosphate, 2% Penicillin/ Streptomycin, 200µM ascorbic acid, and 10%
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FBS). The media were changed every three days for 24 days, at which point cells were
stained with Alazarin Red to verify calcium production.

6.5 Sendai Virus PCR
PCR was performed using isolated genomic DNA from iPSCs in order to verify
Sendai virus removal. It was prepared using the Invitrogen Easy DNA Kit, according to the
manufacturer’s protocol. A 350µl solution A was added to a pellet of iPSCs from one 10cm
dish in order to isolate genomic DNA. Cells were vortexed for 15 sec, then incubated at
65°C for 10 min (in an Eppendorf heat block). A 150µL solution B was added to each tube,
then vortexed vigorously for approximately 20 sec until precipitate moved freely in the tube.
Then, 500µl chloroform was added to each tube and it was vortexed for about 15 sec until
the mixture was homogenous. Next, each tube was centrifuged at 1,200 x g for 20 min at
4°C. The supernatant was aspirated and discarded carefully to not disturb the DNA pellet.
The pellet was washed once in 75% ethanol, then centrifuged at 1,200 x g for 5 min. The
ethanol was removed, then the isolated genomic DNA was resuspended in 100µl of water.
PCR to detect Sendai virus removal was performed using the primers and following
manufacturer’s instructions. PCR was performed using the OneTaq master mix (New
England Biosciences) along with 1µl forward primer (100µM), 1µl reverse primer (100µM),
4.2 µl water, 10 µl OneTaq, and 3.8µl genomic DNA per reaction. The reaction was carried
out as follows: initially denatured at 94°C for 30 sec, 30 cycles of denaturing (94°C, 30 sec),
annealing (52°C, 30 sec), elongation (68°C, 1 min), elongation at 68°C for 5 min, and then
held at 4°C. PCR products were resolved in a 1% agarose gel.

6.6 qRT-PCR
Cells were scraped off a 10cm dish, then resuspended in 1ml 1xDPBS, and
centrifuged at 21,000xg for 1 min. Cells were then resuspended in 1ml of Trizol (Life
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Technologies) and incubated at room temperature for 5 min. Next, 200µL of chloroform
were added, inverted to mix, and incubated for 10 min. The mixture was centrifuged at 1,200
x g for 20 min at 4°C. The aqueous phase was aspirated into a new tube, where RNA was
precipitated using 500µl of isopropyl alcohol. The mixture was incubated for 10 min at room
temperature and then centrifuged again. After washing with 1ml of 75% ethanol, the RNA
pellet was resuspended in 40µl of DNase/RNase-free water. A 4 µg of RNA was used to
make cDNA, according to the reverse transcriptase protocol using iScript Reverse
Transcription Supermix (BioRad). A qPCR was then performed using primers for OCT4,
NANOG, SOX2, and GAPDH (Table 3), according to the protocol using iQ SYBR Green
Supermix (Biorad) on a CFX96 machine (Bio-Rad). The RT-PCR reaction was performed as
follows: 50 °C for 10 min, 95 °C for 5 min, 40 cycles of 95 °C for 10 sec and 60 °C for 30
sec, and 95 °C for 10 min. Results were calculated using the ΔΔCT method and were
normalized to GAPDH expression and are displayed relative to hESC H1.
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Table 3: Primers
Primers

Target

Forward/reverse primer(5′-3′)
CAGATTCGGGCAGCCCAGGTAC

PCR/Sequencing

RECQL4 Exons
11–12

Pluripotency Marker
(qPCR)

TTTGTGGGCCTGAAGAAAACT
NANOG
Oct-4

Pluripotency Marker
(qPCR)

SOX2

Pluripotency Marker
(qPCR)
Pluripotency Marker
(qPCR)
Housekeeping Genes
(qPCR)

AGGGCTGTCCTGAATAAGCAG
AACCTGGAGTTTGTGCCAGGGTTT

Pluripotency Marker
(qPCR)

Pluripotency Marker
(qPCR)

TGAACTTCACCTTCCCTCCAACCA
AGAAGAGGAGAGAGAAAGAAAGGG
AGAGA
GAGAGAGGCAAACTGGAATCAGGA
TCAAA
GACCTCCACAGAGAAGTCGAG

DPPA4

TGCCTTTTTCTTAGGGCAGAG
GCCTTATGTGATGGCTATGTGT

REX1

ACCCCTTATGACGCATTCTATGT

TERT

TGAAAGCCAAGAACGCAGGGATG
TGTCGAGTCAGCTTGAGCAGGAAT
G
CCACTCCTCCACCTTTGAC

GAPDH

ACCCTGTTGCTGTAGCCA
GGATCACTAGGTGATATCGAGC
ACCAGACAAGAGTTTAAGAGATATG
TATC

Sendai Virus Removal (RTPCR)
SeV
Pluripotency Marker (RTPCR)
Pluripotency Marker (RTPCR)
Pluripotency Marker
(qPCR)

ACCCACCTGGTCTGTGTCCCTG

ATGCACCGCTACGACGTGAGCGC
KOS

ACCTTGACAATCCTGATGTGG
TTCCTGCATGCCAGAGGAGCCC

KLF4

AATGTATCGAAGGTGCTCAA

MYC

TAACTGACTAGCAGGCTTGTCG
TCCACATACAGTCCTGGATGATGAT
G
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6.7 Immunofluorescent Staining
iPSCs and iPSC-derived MSCs were fixed with 4% paraformaldehyde (Affymatrix)
for 8 min. Cells were then washed with 500 µl 1XDPBS twice, followed by blocking with
1XDPBS with 10% donkey serum (Jackson ImmunoResearch Labs) and 0.3% Triton X-100
(Sigma) for 1 hr. Then, cells were incubated with primary antibody NANOG (R and D
Systems Cat# AF1997 RRID: AB_355097; 1:1000), TRA-1-81 (R and D Systems Cat#
FAB3195A RRID:AB_663789; 1:500), SSEA4 (R and D Systems FA1435P-025; 1:600),
CD73 (Thermo-Fisher, cat # 41-0200; 1:200), CD44 (Thermo-Fisher, cat # MA5-13890;
1:200), and CD105 antibody (R & D Systems, cat # MAB10971; 1:500) at 4 °C overnight
with gentle rocking. Next, cells were washed twice and stained with secondary antibodies for
1 hr at room temperature in the dark. This was followed by 3 times 1xDPBS washes, then
counterstained with DAPI (1:5000), then stored in 1XDPBS for imaging.

6.8 Alkaline Phosphatase Staining
iPSCs were grown to 80% confluence in 12-well plates, then fixed and stained using
the Alkaline Phosphatase Staining Kit II (Stemgent), according to manufacturer’s
instructions.

6.9 Alizarin Red Staining
One gram of alizarin red was dissolved in 45ml deionized water. The pH was
adjusted to 4.2, then deionized water was added up to 50ml. Fixed osteoblasts were rinsed
2 times with water, then stained for 30 min at room temperature. After staining, cells were
washed twice with water and then ARS staining images were taken.
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6.10 Karyotyping
Karyotyping was performed at either the Cancer Cytogenetics Core Laboratory at
Texas Children’s Hospital or at the Cytogenetics and Cell Authentication Core Facility at The
University of Texas MD Anderson Cancer Center. iPSCs were harvested and G-banded
using standard protocols. Clonal chromosomal changes identified by G-banding were
described according to an International System for Human Cytogenetic Nomenclature ISCN.
Twenty metaphase chromosome spreads at 400 band resolution were analyzed.

6.11 Teratoma
RTS and Family iPSCs were grown in 10 cm dishes to 80% confluence. Cells were
dissociated from the dish, then resuspended in phenol red-free Matrigel (Corning
cat#354262). Immunodeficient NOD SCID mice (Charles River Laboratories) were injected
subcutaneously with 2x107 cells in each flank and observed for palpable teratoma formation.
After approximately six weeks, teratomas were excised and then fixed in 10% formalin
(Sigma). Histology was performed by Histowiz (Brooklyn, New York).

6.12 RNAseq
Cells were isolated for RNA-seq at three different time points: MSC, pre-osteoblasts
(Day 15), and mature osteoblasts (Day 24). RNA samples were prepared by Trizol (Life
Technologies), as described above. RNA sequencing was performed by BGI Genomics and
UTHealth Cancer Genomics Core. DESeq2 analysis was performed, as described (Love et
al., 2014), to normalize all data. GSEA Analysis (Subramanian et al., 2005) was utilized to
identify significant pathways and biological processes between RTS and Family cells at
distinct timepoints. Gene sets that were used were GO_BP, KEGG, as well as the MSigDB
data sets oncogenic signature, TFT, and Reactome. Significant pathways were determined
using a p-value <0.05 and FDR q-value <0.25 (Subramanian et al., 2005). Osteosarcoma
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data sets (2) and osteoblast and bone data sets (4) were requisitioned from the NCBI Gene
Expression Omnibus (accession number GSE36001). These were analyzed using Gene Set
Enrichment Analysis using the GO_BP gene set. Network mapping was done using
Cytoscape (Shannon et al., 2003) for visualization of the dysregulated GO biological
pathways.

6.13 Cell Proliferation Assays
Three thousand osteoblasts per well were plated in a Falcon flat bottom 96-well plate
in 200µl osteogenic differentiation medium with or without IACS-010759 (dissolved in
DMSO, 50nM or 100nM) for three days. Next, 100µl Presto Blue (ThermoFisher), which had
been diluted 1:20 in 1XDPBS, was added to each well and incubated at 37°C for 15 min.
Then, the plates were read at 570 nm absorbance.

6.14 Enzymatic Assays
Electron transport chain (ETC) enzyme activity was performed using previously
described procedures (Chen et al., 2019). Briefly, RTS and Family osteoblasts from a 10cm
dish were dissociated and washed with cold 1XDPBS. Cell pellets were frozen at -80°C until
the assay was run. Cells were lysed and the protein concentration was determined by the
Bradford assay. ETC enzyme activity was analyzed in triplicate using Tecan Infinite M200,
as previously described (Ma et al., 2010). The same protein concentration was used for ETC
complexes and citrate synthase (CS) activity measurements in order to normalize activity.

6.15 Seahorse Assays
Seahorse assays were carried out according to the manufacturer’s protocol, with the
modifications and specifications described, here. Thirty thousand cells (Day 17 osteoblasts)
were added to each well of a Seahorse cell culture plate in 200µl osteogenic differentiation
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media (ODM), with the exception of a minimum of four blank wells per assay. Cells were
incubated at 37°C for three days. The assay plate was prepared by incubating in water
overnight, then in calibration media for a minimum of 4 hr before the assay began. Next,
180µL of assay media, prepared with 10mM pyruvate, 2mM glutamine, 25mM glucose, and
4mg/ml BSA, were added to each well. The tissue culture plate then was incubated at 37°C
without CO2 and humidity. Assay chemicals were prepared using the assay media without
BSA. When testing IACS 010759, these were added to well A or to assay media as noted
and incubated for the indicated duration at 37°C. The assay measurements were at baseline
for 18 min (3 cycles of 3-min mix and 3-min measure), complex I inhibitor injection from port
A for 30 min (immediate measurement, then 5 cycles of 3-min mix and 3-min measure), then
15µM Oligomycin (port B), 30µM FCCP, and 5µM Rotenone/ Antimycin A, each for 18 min.
Immediately following each assay, cells were fixed by removing assay media, gently
washing with 200µl 1XDPBS, then adding 100µl 4% paraformaldehyde for 8 min. After
fixation, cells were gently rinsed again twice with 200µl 1XDPBS, then stained immediately
with DAPI diluted in 1XDPBS at 1:5000. Cell numbers were counted using a Biotek
Lionheart automatic microscope with default settings for TPP 96-well TC flat bottom plates.
Nuclei were counted by thresholding for a minimum size of 5µm and a maximum size of
50µm, including edge objects. OCAR and ECAR were calculated using the Wave software,
normalized to total cell number.
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